65,437 trials
Post Market Surveillance Study Following Clinical Routine
Primary: Percentage of Participants Without CRT-P Device Related Complications — 100 % of participants — p=<0.001
Advanced Solid Tumors · Relapsed/Refractory Lymphoma
Primary: Cmax: Maximum Observed Concentration of Alisertib in Presence and Absence of Itraconazole in Part A — 1060.3; 1002.8 nmol/L
Tinea Pedis
Primary: Number of Participants With Complete Cure: Post Treatment (Day 17) — 0; 4 Participants
Osteoporosis
Primary: Long-term Safety of Zoledronic Acid for the Treatment of Osteoporotic Children Treated With Glucocorticoids. — 7; 12; 3; 0 Participants
Intermittent Claudication · Peripheral Vascular Disease
Primary: Change From Baseline in Initial Walking Distance — 64.3 metres
Neonatal Screening
Primary: Comprehension for Biobanking at Time of Consent — .699; .645 score on a scale — p=<.001
Nasolabial Fold
Primary: Treatment Differences in Pain (Restylane Perlane Side - Restylane Perlane Lidocaine Side) as Measured by a Visual Analogue Scale (VAS) — 87.1 percentage of subjects
Duarte Galactosemia
Primary: Children's Memory Scale Score — 106.76; 104.15; 105.99; 103.78 score on a scale
Nicotine Dependence, Other Tobacco Product · Bladder Cancer · Lung Cancer
Primary: Change in Daily Cigarette Smoking Given 10 or More E-cigarette Sessions in a Day — 4.37 number of Daily Cigarettes
Urolith
Primary: Change in Percentage of Total Microflora Between Urolithin Excretors and Non-excretors — 60; 68; 56; 70 percentage of total microflora — p=0.012
Neuromuscular Block · Renal Transplant Donor of Left Kidney · Renal Transplant Donor of Right Kidney
Primary: Total Score of the Quality of Recovery-40 Questionnaire (QoR-40) — 169.3; 169.5 score on a scale
Type 2 Diabetes Mellitus
Primary: Constrained Longitudinal Data Analysis of Change From Baseline in Hemoglobin A1c (HbA1c) at Week 16 Excluding Data After Glycemic Rescue (Phase A) — -0.61; 0.29 Percent…
Myopia
Primary: Change in Axial Elongation in the Two Study Phases — 0.163; 0.047 mm
Healthy
Primary: Plasma Ellagic Acid Concentration 0 to 24 Hours Post-dose Area Under the Curve — 0.074; 0.075 micromol*h/L — p=0.82
Cervical Abnormalities · Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Cancer
Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…